Valuation models
price $551.21 · as of Nov 2, 2026
DCF · Perpetuity growth · 5yused198.68 – 263.13226.56143% overvaluedDCF · Perpetuity growth · 10y228.66 – 303.31260.95111% overvaluedDCF · EBITDA exit · 5y319.13 – 347.08332.7466% overvaluedDCF · EBITDA exit · 10y322.69 – 375.06347.6759% overvaluedP/E · peers181.67 – 542.72362.2052% overvaluedP/E · own history603.40 – 831.31693.3521% undervaluedPEG—206.13167% overvaluedEV/EBITDA · peers235.57 – 337.70257.20114% overvaluedEV/Revenue · peers188.18 – 338.21238.77131% overvaluedEarnings power value73.94 – 102.0185.96541% overvaluedWall St. consensus target—710.0022% belowCost of capital (WACC)—10.45%—
DCF · Perpetuity growth · 5y leads for profitable growth — positive operating income and three years of positive free cash flow. How the headline model is chosen.
Model value · DCF · Perpetuity growth · 5y
226.56
Idexx Laboratories closed at $551.21 — overvalued by 143% vs model.
198.68the model's range263.13
DCF · Perpetuity growth · 5y leads for profitable growth — positive operating income and three years of positive free cash flow. From a five-year discounted cash flow.
Other models
85.96 – 693.35
Wall St. target
710.00 22% below
Above model, 1y
30 of 30 days
How it is valued
Valued asProfitable Growth
Low/slowing growth (~8% recent)High profitability (25% net margin)Moderately volatile earnings
Model estimates for research reference only, not investment advice. Every model rests on assumptions that may not match what happens; how each model works is in the manual.